AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 101 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2023. The put-call ratio across all filers is 0.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $226,085 | -32.9% | 21,950 | +7.3% | 0.00% | -33.3% |
| Q2 2023 | $337,016 | +162.8% | 20,450 | +46.1% | 0.00% | +200.0% |
| Q1 2023 | $128,240 | +14.4% | 14,000 | -10.5% | 0.00% | 0.0% |
| Q4 2022 | $112,054 | -100.0% | 15,650 | -83.3% | 0.00% | -66.7% |
| Q3 2022 | $235,235,000 | +317785.1% | 93,800 | +208.6% | 0.00% | +200.0% |
| Q2 2022 | $74,000 | -76.7% | 30,400 | -34.7% | 0.00% | -66.7% |
| Q1 2022 | $318,000 | +16.9% | 46,550 | +38.3% | 0.00% | 0.0% |
| Q4 2021 | $272,000 | +177.6% | 33,650 | +236.5% | 0.00% | +200.0% |
| Q3 2021 | $98,000 | +46.3% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $67,000 | -25.6% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $90,000 | +34.3% | 10,000 | -0.2% | 0.00% | 0.0% |
| Q4 2020 | $67,000 | -99.9% | 10,017 | +0.2% | 0.00% | 0.0% |
| Q3 2020 | $50,000,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |